Aiming to Accelerate Development of Innovative New Drugs and Advanced Regenerative Medicine Therapeutics
BXPLANT, a CDRO specializing in clinical development and clinical trial execution, announced on the 7th that it has signed a Memorandum of Understanding (MOU) with Kyungpook National University Hospital Clinical Trial Center and Kyungpook National University Hospital Advanced Clinical Trial Center to formalize strategic cooperation in clinical trials and clinical development.
This agreement was pursued with the goal of promoting the development of innovative new drugs and advanced regenerative medicine therapeutics for domestic and international pharmaceutical and bio companies. Both organizations plan to create synergy across the full clinical trial cycle based on their respective expertise and infrastructure. Additionally, they will continue strategic cooperation to expand the clinical ecosystem centered on regional hub medical institutions.
Comprehensive Collaboration Framework
Under the agreement, BXPLANT will provide CDRO-based services including clinical development strategy formulation, clinical trial design and operations, and project management. Kyungpook National University Hospital Clinical Trial Center and Advanced Clinical Trial Center will support medical staff for clinical trial execution, subject recruitment networks, and clinical infrastructure. Through this collaboration, the organizations plan to advance systems to enable global-level clinical trial execution even outside the capital region.
In particular, both organizations will focus on expanding clinical research opportunities led by regional medical institutions in innovative therapeutic areas including cell and gene therapy, regenerative medicine, and other advanced therapeutics. This is significant in supporting domestic biotech and venture companies to conduct clinical trials in diverse clinical environments rather than being concentrated in specific regions.
Improving Patient Access and Clinical Data Quality
This collaboration is also expected to have positive effects in terms of improving regional patients’ access to clinical trials. By expanding region-based clinical trials, the organizations anticipate reducing patient travel burdens and including more diverse patient populations in clinical studies, thereby simultaneously enhancing the representativeness and quality of clinical data.
A BXPLANT representative stated, “This MOU is significant in that it complements the capital region-centered clinical trial structure and establishes a foundation for regional hub hospitals to participate as core partners in clinical development. We will simultaneously pursue balanced regional development of domestic clinical trials and strengthened global competitiveness.”
A representative from Kyungpook National University Hospital Clinical Trial Center also stated, “Through collaboration with BXPLANT, we will create an environment where regional medical institutions can proactively conduct clinical trials and establish momentum to grow into a clinical trial hub representing the Daegu-Gyeongbuk region.”
Both organizations plan to establish a regionally-centered clinical trial model through this agreement and promote sustainable growth of the domestic clinical trial ecosystem.
source : BXPLANT Signs MOU with Kyungpook National University Hospital Clinical Trial Center—”Activating Regional Hub Clinical Trials”, Hee-yeon Cho, New Daily, 2026.01.07., https://biz.newdaily.co.kr/site/data/html/2026/01/07/2026010700261.html
